New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

Core Insights - ZORYVE cream 0.15% has shown consistent efficacy in improving atopic dermatitis (AD) symptoms across diverse racial and ethnic groups, as well as different Fitzpatrick skin types [1][2][3] - The treatment was found to be safe and well tolerated among all subgroups, with low incidence of treatment-emergent adverse events [4] Efficacy Results - At Week 4, ZORYVE-treated patients demonstrated higher percentages of Validated Investigator Global Assessment for AD (vIGA-AD) Success compared to vehicle-treated patients across all racial and ethnic groups [2] - Specific success rates included: White: 32.3% vs. 13.3%, Black or African American: 25.8% vs. 11.5%, Asian: 33.7% vs. 21.8%, and Others: 33.2% vs. 13.7% [2] - Improvements in itch were also significant, with ZORYVE-treated patients achieving a ≥4-point improvement in Worst Itch-Numeric Rating Scale (WI-NRS) Success across all subgroups [3] Safety Profile - The incidence of treatment-emergent adverse events (TEAEs) was low and similar across ZORYVE and vehicle-treated patients, indicating favorable local tolerability [4] - Common adverse reactions included headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%) [9] Company Overview - Arcutis Biotherapeutics, Inc. is focused on developing innovative treatments for immune-mediated dermatological diseases, with ZORYVE being part of their growing portfolio [10] - The company emphasizes the importance of clinical data representing diverse populations to ensure effective treatment options for all patients [4]